Skip to main content
Terug
Watch Compare

Finch Therapeutics Group, Inc.

Datakwaliteit: 100%
Ook genoteerd als FNCHQ OTC
FNCH
OTC Manufacturing Chemicals
€ 9,20
€ 0,00 (0,00%)
Marktkapitalisatie: 14,77 M
Prijs
€ 9,20
Marktkapitalisatie
14,77 M
Dagbereik
€ 5,01 — € 11,91
52-Weeksbereik
€ 2,00 — € 16,10
Volume
71.791
Openen € 11,90
50D / 200D Gem.
€ 12,77
27,95% below
50D / 200D Gem.
€ 12,96
29,01% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -18,04 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-87,57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-85,20%
Onder sectorgemiddelde (-53,34%)
ROIC-35,14%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio3,87
Interest CoverageN/A

Waardering

PE (TTM)
-1,04
Boven sectorgemiddelde (-1,47)
P/B Ratio1,04
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B 1,0 1,6
ROE % -85,2 -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q22023 -€ 4,50 -€ 3,83 +14,9%
Q12023 -€ 2,70 -€ 10,73 -297,2%
Q42022 -€ 10,20 -€ 16,75 -64,3%
Q32022 -€ 13,50 -€ 13,23 +2,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -87,57% Revenue Growth (3Y) -92,40%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -14,17 M
ROE -85,20% ROA -29,62%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -18,04 M
ROIC -35,14% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,87
Interest Coverage N/A Asset Turnover 0,00
Working Capital 12,82 M Tangible Book Value 14,22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,04 Forward P/E N/A
P/B Ratio 1,04 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -122,12%
Market Cap 14,77 M Enterprise Value -1,26 M
Per Share
EPS (Diluted TTM) -8,80 Revenue / Share 0,00
FCF / Share -11,24 OCF / Share -11,24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 127,35%
SBC-Adj. FCF -19,60 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2023 FY2022 FY2021
Revenue 107.000,0 861.000,0 18,53 M
Net Income -74,75 M -114,65 M -58,16 M
EPS (Diluted) -46,59 -2,40 —
Gross Profit — — —
Operating Income -83,86 M -115,59 M -59,99 M
EBITDA — — —
R&D Expenses 7,20 M 57,89 M 57,28 M
SG&A Expenses — — —
D&A 1,52 M 5,51 M 2,30 M
Interest Expense — — —
Income Tax -3,46 M 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2023 FY2022 FY2021
Total Assets 55,37 M 162,94 M 225,37 M
Total Liabilities 32,49 M 67,23 M 23,15 M
Shareholders' Equity 22,89 M 95,71 M 202,22 M
Total Debt 0,0 15,00 M 0,0
Cash & Equivalents 25,12 M 71,04 M 133,48 M
Current Assets 25,85 M 74,55 M 142,55 M
Current Liabilities 4,08 M 14,69 M 14,79 M